| 摘要 |
PURPOSE: A conjugate containing carboxylic acid and non-antigenic hydrophilic biocompatible polymer is provided to minimize physiological activity reduction of erythropoietin and to enhance drug efficiency in the human body. CONSTITUTION: A conjugated of biocompatible polymer and EPO(erythropoietin) is prepared by binding biocompatible polymer with C-terminal of EPO by carboxyl group. The EPO is derived from human. The biocompatible polymer is polyethylene glycol(PEG). The molecular weight of PEG is 1,000-100,000. The biocompatible polymer is bound to the carboxyl group of EPO in mole ratio of 1:1. A pharmaceutical composition for treating or preventing anemia and hematopoiesis-relating diseases contains the conjugate of biocompatible polymer and EPO and pharmaceutically acceptable carrier.
|
